These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11768671)

  • 21. Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation.
    de Bildt A; Mulder EJ; Scheers T; Minderaa RB; Tobi H
    Pediatrics; 2006 Dec; 118(6):e1860-6. PubMed ID: 17142506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A guide to psychopharmacological treatment of patients with intellectual disability in psychiatry.
    Molina-Ruiz RM; Martín-Carballeda J; Asensio-Moreno I; Montañés-Rada F
    Int J Psychiatry Med; 2017 Mar; 52(2):176-189. PubMed ID: 28792289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Psychotropic Polypharmacy Among Outpatients With Psychiatric Disorders and Intellectual Disability.
    Lunsky Y; Modi M
    Psychiatr Serv; 2018 Feb; 69(2):242-246. PubMed ID: 29089006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Behavioral disorders and substance abuse in adolescents with mental retardation].
    Papachristou E; Anagnostopoulos D
    Psychiatriki; 2014; 25(2):139-50. PubMed ID: 25035183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis.
    Gierisch JM; Nieuwsma JA; Bradford DW; Wilder CM; Mann-Wrobel MC; McBroom AJ; Hasselblad V; Williams JW
    J Clin Psychiatry; 2014 May; 75(5):e424-40. PubMed ID: 24922495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation.
    Singh NN; Ellis CR; Donatelli LS; Williams DE; Ricketts RW; Goza AB; Perlman N; Everly DE; Best AM; Singh YN
    J Intellect Disabil Res; 1996 Feb; 40 ( Pt 1)():1-7. PubMed ID: 8930051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ECT: use in individuals with mental retardation.
    Friedlander RI; Solomons K
    J ECT; 2002 Mar; 18(1):38-42. PubMed ID: 11925520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The international consensus process on psychopharmacology and intellectual disability.
    Reiss S; Aman MG
    J Intellect Disabil Res; 1997 Dec; 41 ( Pt 6)():448-55. PubMed ID: 9430048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey.
    Perry BI; Cooray SE; Mendis J; Purandare K; Wijeratne A; Manjubhashini S; Dasari M; Esan F; Gunaratna I; Naseem RA; Hoare S; Chester V; Roy A; Devapriam J; Alexander R; Kwok HF
    J Intellect Disabil Res; 2018 Feb; 62(2):140-149. PubMed ID: 29349928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological management of behavioral and psychiatric symptoms in older adults with intellectual disability.
    Eady N; Courtenay K; Strydom A
    Drugs Aging; 2015 Feb; 32(2):95-102. PubMed ID: 25573538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mood and anxiety symptoms in an adolescent with Pervasive Developmental Disorder Not Otherwise Specified and moderate mental retardation.
    Williams DT; Hirsch S; Coffey B
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):721-6. PubMed ID: 17979592
    [No Abstract]   [Full Text] [Related]  

  • 32. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues.
    Szymanski L; King BH
    J Am Acad Child Adolesc Psychiatry; 1999 Dec; 38(12 Suppl):5S-31S. PubMed ID: 10624083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychopharmacotherapy in children and adults with intellectual disability.
    Santosh PJ; Baird G
    Lancet; 1999 Jul; 354(9174):233-42. PubMed ID: 10421318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States.
    Houghton R; Ong RC; Bolognani F
    Autism Res; 2017 Dec; 10(12):2037-2047. PubMed ID: 28963809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatments for the challenging behaviours of adults with intellectual disabilities.
    Matson JL; Neal D; Kozlowski AM
    Can J Psychiatry; 2012 Oct; 57(10):587-92. PubMed ID: 23072949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.
    Baumeister AA; Todd ME; Sevin JA
    Clin Neuropharmacol; 1993 Aug; 16(4):271-94. PubMed ID: 8374912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Particular aspects of psychiatric management of mentally retarded patients with psychiatric disorders].
    Hennicke K; Meins W
    Psychiatr Prax; 1995 Nov; 22(6):240-3. PubMed ID: 8570755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of psychotropic medications in children with developmental disabilities.
    Calles JL
    Pediatr Clin North Am; 2008 Oct; 55(5):1227-40, ix. PubMed ID: 18929062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychiatric hospital treatment of children with autism and serious behavioral disturbance.
    Siegel M; Gabriels RL
    Child Adolesc Psychiatr Clin N Am; 2014 Jan; 23(1):125-42. PubMed ID: 24231172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [How many children and adolescents do receive a combined behavioral and psychopharmacological therapy?].
    Sinzig J; Blanz S; Schmidt MH; Lehmkuhl G
    Prax Kinderpsychol Kinderpsychiatr; 2008; 57(2):85-97. PubMed ID: 18396847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.